Tuesday 15 December 2020
Investor Ideas #Potcasts #Podcast - Episode 507, #Cannabis News and #Stocks on the Move: (CSE: $PULL.C) (OTCQB: $DRVD) (CSE: $HOLL.C) (CSE: $STEM.C)
Investor Ideas #Potcasts #Podcast - Episode 507, #Cannabis News and #Stocks on the Move: (CSE: $PULL.C) (OTCQB: $DRVD) (CSE: $HOLL.C) (CSE: $STEM.C)
Delta, Kelowna, BC, December 15, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/121520-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/12151PULL-DRVD-HOLL-STEM.asp
Hear the investor ideas potcast on
Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be looking at a few private and public company
announcements.
Pure Extracts Technologies Corp. (CSE: PULL), a plant-based extraction company
focused on cannabis, hemp, and the rapidly emerging functional mushroom sector,
announced their support of Health Canada’s
proposed intent to revise the Special Access Programme (SAP) and related
regulations to permit certain authorized uses of psilocybin-assisted
psychotherapeutic treatments. The intended SAP revision, announced on December
11th, could lead to important new medical applications, particularly in the
complex and growing mental health sector.
Health
Canada’s announcement could act as a milestone achievement driving advanced
research initiatives forward. This includes several ongoing clinical trials
that consistently indicate breakthrough therapy potential of
psilocybin-assisted psychotherapy for a number of mental health patients suffering
from conditions where conventional therapies have failed or have proven
unsuitable.
The
proposed SAP update emphasizes the strategic importance of Pure Extracts
engagement of a globally recognized operations, compliance, and regulatory
consulting firm to advise on the Company’s application to Health Canada for a
Dealers Licence under the Controlled Drugs and Substances Act (CDSA). The CDSA
and its Regulations provide the framework for legal access to controlled
substances, and the control and regulation of production, distribution, and
sale. One of Health Canada’s responsibilities is to provide the licensing and
oversight framework for the legal production of controlled substances.
Upon
acceptance, a Dealer’s License could allow Pure Extracts to engage in the
following activities:
● Procurement
of controlled substances, including by import, synthesis, propagation,
cultivation and harvesting of psychedelic mushrooms for psilocybin extraction
●
Research and manufacture of controlled
substances such as psilocybin and psilocin
●
Business to business sale of controlled
substances, including by export
● Sale of
controlled substance via pharmacies
Expanding
upon the strategic importance of the SAP review, Pure Extracts recently
announced a collaboration with Dr. Alexander MacGregor as a key scientific
advisor to the Company. Pure Extracts and Dr. MacGregor are collaborating on
the development and research of optimum psilocybin extraction methodologies in
preparation to service the needs of the rapidly advancing growth and demand in
the sector.
As
previously noted, Dr. MacGregor is the Dean of Faculty, a distinguished
Professor of Biopharmaceutics, and current President of the Toronto Institute
of Pharmaceutical Technology (TIPT) – North America’s premier post-graduate
institute of pharmaceutical sciences, technology and research. He is also the
CEO of TIPT’s parent company, Transpharm Canada Inc., which holds a Health
Canada Drug Establishment License, a Cannabis Drug License, and a Dealer’s
License issued under the Controlled Drugs and Substances Act (CDSA). Transpharm
Canada conducts clinical trials, drug development and is licensed to possess
psychedelic drug compounds.
Pure
Extracts CEO Ben Nikolaevsky states, “The Special Access Programme may prove to
be the tipping point and fundamental milestone event that eventually transforms
an entire segment of the medical community’s outlook towards the treatment of
mental health conditions. With greater and more open access to trials,
researchers can move towards larger and more comprehensive studies eventually
including thousands of patient candidates. Through multiple large-scale
studies, we see great promise in determining treatment safety, efficacy, and
desired outcomes. Our research suggests a broad spectrum of products
encompassing multiple formulations will be required to service demand across
potentially intensive therapies through to microdosing protocols. Exact
formulations and high-quality products will be required, and that is
fundamentally the sort of work we understand and excel at. Here at Pure
Extracts, we believe in the future of the mushroom-based drug development
sector and are committed to building value based on the growing number of
positive indicators for future success.”
Driven Deliveries, Inc. (OTCQB: DRVD), one of California's
fastest-growing e-commerce cannabis retailers and direct-to-consumer logistics
companies, today announced it has secured preliminary
approval for a new e-commerce delivery hub in the Fresno County region. Driven has also submitted its application for
this new cannabis non-storefront retail license to the State of California
which is expected to be approved in the near-term. Plans for Driven's acquisition by Stem Holdings, Inc. (OTCQX: STMH) (CSE: STEM) later this month are continuing on
schedule, creating Driven By Stem trading
under Stem's current symbols.
This new
strategically-located hub will enable Driven to serve central California with
greater efficiency and speed, and will be led by key experienced employees
transferring to this location to ensure a smooth and flawless launch. This is expected to create 50 new jobs in the
local area and afford significant cost savings in both general and
administrative costs, as well as local taxes, with savings of $1.2 million
annually vs. servicing this market from a remote hub.
"Securing a license in Central California
is a key component in Driven's focus on building market share with increasing
operational efficiencies in new and current markets," commented Salvador
Villanueva, interim CEO of Driven, and founder of its Budee e-commerce brand
acquired earlier this year. "Our
focus on expanding our footprint in California with our Budee and Ganjarunner
e-commerce stores as well as new markets will be the key to driving
profitability in 2021," he concluded.
"We
are pleased that this first step in our plan to integrate Driven into Stem's
operations is nearing completion," stated Adam Berk, CEO of Stem
Holdings. "Sal and the team have
made great strides over the last 60 days as part of our 'On Your Mark'
initiative to prepare for a seamless assimilation of Driven that will quickly
build value for our shareholders," he remarked.
Driven
currently has delivery hubs located in Oakland and Los Angeles, California, and
will be expanding to the Oregon market in which Stem already operates by
year-end.
Hollister
Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) has its roots in the birthplace of
the American biker, and Easyriders has been the definitive voice of motorcycle
culture for half a century. As part of Easyriders' 50th-anniversary
celebration, the Company signed an exclusive agreement with
Hollister Biosciences to introduce a national line of cannabis products that
embody the biker spirit and ethos. It is
anticipated that the new line will make its debut next month with pre-rolls and
mini pre-rolls, followed by a cannabis tattoo balm that's applied directly to
the skin after new ink, with a full line of products coming in 2021.
The Company feels the market
potential for these products is significant, but so is the cultural
significance considering the two companies involved.
Easyriders magazine debuted shortly
after the groundbreaking 1969 film Easy
Rider in which Peter Fonda and Dennis Hopper portray bikers traveling across
the American Southwest. Similarly, Hollister Biosciences is based in Hollister,
California, home to an infamous 1947 biker rally that birthed the outlaw biker
image and inspired the Marlon Brandon film The
Wild One. Cannabis, which had developed its own outlaw culture a few
decades before, became a staple among bikers in the late '60s onward. As
epitomized in the pages of Easyriders, this vibrant biker culture grew beyond
its outlaw origins to inspire an independent spirit that embraces exploration,
Americana and the sense of freedom that only comes from riding.
This is a culture that accepts
nothing less than total authenticity. That includes its choice in cannabis, and
that is why Hollister Biosciences and Easyriders were destined to take this
ride together. From their historic roots in biker culture to their embrace of
its visual iconography, these companies will offer the first truly authentic
cannabis products for one of the most iconic cultures in modern American
history.
"My vision for Hollister has
always been to pay homage to the amazing biker culture that has permeated the
global landscape over the past few decades by combining it with amazing
cannabis products," says Carl Saling, the Co-Founder, CEO and Director of
Hollister Biosciences. "Easyriders is one of the most iconic and
recognizable global biker brands. We are proud to be their exclusive cannabis
partner, and we look forward to producing a truly authentic experience across
the cannabis SKUs we develop and distribute across America."
Hollister Biosciences, whose
products are currently found in nearly 300 dispensaries in California and more
than 80 in Arizona, takes a seed-to-shelf approach that carefully scales up
small-farm style production that meets the highest quality standards. As part
of the new agreement, the company will introduce Easyriders pre-rolls and
tattoo balms into the California market in early 2021 with a full line of
products to follow. Like an eastbound ride on Route 66, Arizona comes next, and
the rest of the American markets will follow.
Pepper Foster, President of
Easyriders, stated, "My vision for Easyriders has been to pay homage to
the 50 years of this iconic magazine and to Joe Teresi who launched Easyriders
in the late 1960s. The first magazine hit the stands in June 1970, and 50 years
later, we are proud to carry the torch, expanding upon that yen to be devoid of
restraint by taking a broader look at what it means to be a biker in the 21st
century while staying connected to our original roots. In continuing our
commitment to authenticity, we are proud and excited to partner with another
iconic brand, Hollister. We invite you to take the ride with us. Ride hard.
Ride fast."
The terms of the deal are; 2-year
exclusive agreement on all cannabis products in the US with an 80:20 net
revenue split in favour of Hollister with options to renew for subsequent
terms.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade
these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and
others.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor
Ideas – news, articles, podcasts and stock
directory
Monday 14 December 2020
Friday 11 December 2020
Thursday 10 December 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; #Podcast 506 (OTC: $LRSV) (TSX: $AH.TO) (TSXV: $KHRN.V) (TSX: $AVCN.TO) (CSE: $PULL.C)
Investor Ideas #Potcasts,
#Cannabis News and #Stocks on the Move; #Podcast 506 (OTC: $LRSV) (TSX: $AH.TO)
(TSXV: $KHRN.V) (TSX: $AVCN.TO) (CSE: $PULL.C)
Delta, Kelowna, BC, December 10, 2020 (Investorideas.com
Newswire) www.Investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast
edition of cannabis news and
stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/121020-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/12101LRSV-AH-KHRN-AVCN-PULL.asp
Hear the investor ideas potcast on
Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be looking at a few private and public company
announcements.
Link
Reservations Inc. (OTC:
LRSV), a provider of cannabidiol (CBD) products
specifically tailored for pets, announced that it
is current with all of its OTC Market filings and has achieved "Current
Information" status, with no risk or yields signs associated with the
stock on OTCMarkets.com.
"I am delighted that the
Company is current once again and we can focus back on the business,"
commented Rene Lauritsen, LinkResPet CEO. "We continue to explore the
potential for growth in the CBD and wellness market and are currently assessing
a number of avenues through which we can expand our presence, including further
developing our product range," he added.
The Company has updated all
financial reports and disclosure statements and will resume operations with its
LinkResPet brand, making further announcements as new developments arise.
The Company also recently raised its
Authorized Shares in order to issue shares to its CEO, Rene Lauritsen, for an
acquisition that is pending which he initiated. These newly issued shares are
restricted for one year per Rule 144 and if the acquisition is not completed
the shares will be returned to treasury. As shareholders may note, LRSV's share
structure had previously been unchanged for almost four years.
Aleafia
Health Inc. (TSX:
AH)
(OTC:
ALEAF) announced that it
will commence cannabis exports to the Israeli medical cannabis market. The
Company signed a binding letter of intent with Equinox International Ltd., a
licensed British medical cannabis company with operations in the Israeli
market.
Under the LOI, Equinox has committed
to purchasing approximately 1,400 kg of dried flower in 2021. The first
shipment to Equinox is expected to occur in Q1 2021 pending receipt of
necessary import and export permits and completion of Aleafia’s cultivation
cycle. Permit applications have already been submitted and will mark the first
export of EU GACP-compliant dried flower grown at Aleafia’s Niagara Greenhouse
facility.
Israel, the world’s fastest growing
medical cannabis market, reached over 60,000 registered patients in 2020, from
half that figure in 2018. It is also the largest net importer of cannabis
globally, recently surpassing Germany.
Equinox International, in
partnership with Aleafia Health, will establish an Israeli Land-to-Brand
ecosystem covering supply, distribution, market leading brands and retail.
“Gaining market access to Israel, an
incredibly dynamic country with a fast growing, highly innovative cannabis
market, is something we’ve long aspired to,” said Aleafia Health CEO Geoffrey
Benic. “Doing so with Equinox, an accomplished, internationally scaled partner,
marks an exciting chapter as we commercialize Aleafia Health globally.”
“Equinox is delighted to form a
Land-to-Brand strategic partnership with Aleafia Health,” said Equinox
International CEO Xan Morgan. “Equinox is firmly positioned as a British
champion and in partnership with Aleafia will be a leader in the Israeli cannabis
market.”
The parties must now negotiate a
definitive agreement concerning the supply of dried flower to Israel over a
three-year term. They have agreed to negotiate the definitive agreement
exclusively with one another for a period of 45 days.
Khiron
Life Sciences Corp. (TSXV:
KHRN) (OTCQX:
KHRNF), a vertically integrated cannabis leader with core
operations in Latin America and Europe,
announced that it has now successfully completed the import of
its High THC medical cannabis product into Peru, with first prescriptions to be
filled in December.
With today's announcement, Khiron
becomes the first company to export High THC medical cannabis from Colombia and
the only Colombian company to fill High THC prescriptions in Peru for
commercial purposes. This expands the Company's product offering in Peru where
sales of its High CBD product began in September 2020.
"This first shipment of
Khiron's trusted High THC product into Peru represents a first in exporting
High THC medical cannabis from Colombia and delivers on our strategy to
increase our market impact in Peru, providing patients with reliable access to
medical cannabis products. With an established pharmacy partner and data from
medical cannabis prescriptions we have filled to date in Colombia, we know this
will make a difference in improving the quality of life for patients in
Peru," commented Alvaro Torres, Khiron CEO and Director.
As part of Khiron's Latin America
expansion strategy, its High THC medical cannabis products were successfully
imported into Peru as result of the Company completing all export, import and
distribution requirements, including approved receipt of quotas for the
Company's high THC medical cannabis by DIGEMID, Peru's drug regulatory
authority. Khiron Peru is a GSP certified, registered pharmaceutical
establishment, and Farmacia Universal has all required permits and licenses,
including Good Manufacturing Practices (GMP) certification, to prepare
magistral preparations with medical cannabis and distribute final products to
patients through pharmacies under the previously announced agreement with
Khiron.
The Company continues to expand
medical cannabis doctor education, with almost 200 physicians from Peru having
obtained their diploma accrediting completion of Khiron's medical education
through the Company's program with Tecnologico de Monterrey. The Company's high
THC products will focus on helping patients with serious conditions that
include chronic pain, spasticity, PTSD, nausea, insomnia, anorexia and
depression.
Avicanna
Inc. (TSX:
AVCN) (OTCQX:
AVCNF), a biopharmaceutical company focused on the
development, manufacturing and commercialization of plant-derived
cannabinoid-based products announced the
launch of its medical cannabis program in Colombia, under compound pharmacy
legislation “Formulaciones Magistrales”, in which Avicanna will provide its
standardized, industry-leading cannabinoid formulary to patients and the
medical community. Additionally, this program includes the education and
training of the medical community and a comprehensive patient support program.
Aras Azadian, CEO of Avicanna Inc.,
commented: “After 2 years of preparation, we are proud to be launching this
complete program in a market that is very significant to us and to be doing so
with a medical community that we have been working closely with for close to 3
years. We believe that this medical program will set the gold standard for
advanced cannabinoid-based medicine in Colombia and will act as a proof of
concept for planned expansions into other Latin American markets.”
The pharmaceutical cannabinoid
preparations, which require physician prescription, will be commercialized
through a range of business models including direct sales to patients, delivery
to national pharmacies and delivery to third party medical institutions across
Colombia. This comprehensive medical cannabis program is the first of its kind
in Colombia to be educating and training third party health care practitioners
on the efficacy of advanced cannabinoid-based medicine across various clinical
indications and comorbidities and providing appropriate cannabinoid solutions.
The target therapeutic areas include neurological disorders such as epilepsy,
Parkinson’s disease, multiple sclerosis, psychiatric indications such as PTSD,
anxiety, depression as well as chronic pain.
This first complete portfolio of
advanced cannabinoid preparations comprises the same scientifically developed
formulations as Avicanna’s Canadian RHO Phyto branded dosage forms including
topicals, oil drops, sublingual sprays, and capsules in range of CBD only and
CBD-THC ratios. The products are subjected to typical pharmaceutical drug
development, including stability studies and preclinical analysis where they
have demonstrated superior stability and bioavailability in comparison to basic
MCT oil formulations. Avicanna continues to advance these formulations through
real world evidence trials and further preclinical studies with leading
Canadian institutions and clinicians. In addition to its R&D efforts, the
Company continues to optimize its current formulas and expand its pipeline of
products to include alternative delivery mechanisms. The active pharmaceutical
ingredients for this program are sourced from Avicanna’s majority owned
subsidiary Santa Marta Golden Hemp S.A.S., where the cannabinoids are extracted
from organic and sustainably cultivated plants.
The final preparation of these
products is completed through Avicanna’s own Good Production Practices (GPP)
certified pharmacy lab in Bogota through its wholly owned subsidiary Avicanna
LATAM S.A.S. (“Avicanna LATAM”), which is believed to be the first of its kind
to be certified for cannabinoid preparations. The education and patient support
programs are also managed and operated by Avicanna’s medical team to ensure the
services meet Avicanna’s quality standards and complete the full vertical
integration.
“At Avicanna, our focus has always
been on patients, and today, with the launch of our medical program, patients
in Colombia will have access to therapeutic alternatives that may contribute to
the control of their comorbidities, improving their quality of life and solving
possible unmet medical needs altogether. With that, we have established
ourselves as a significant contributor to the health system in Colombia, where
we intend to also introduce novel pharmaceutical forms and provide optimal
care,” stated Dr. Carlos Maldonado, Senior Vice President, Clinical Development
at Avicanna LATAM.
Pure Extracts Technologies Corp. (CSE:
PULL) announced that it
has engaged a globally recognized operations, compliance, and regulatory
consulting firm to advise on the Company’s application to Health Canada for a
Dealers Licence under the Controlled Drugs and Substances Act (CDSA).
The CDSA
and its Regulations provide, among other things, the framework for legal access
to controlled substances, and the control and regulation of production,
distribution, and sale. One of Health Canada’s responsibilities is to provide
the licensing and oversight framework for the legal production of controlled
substances.
Under
this framework, a company is required to obtain a licence issued by Health
Canada in order to conduct various activities with controlled substances.
Licence holders are responsible for compliance with the CDSA and its
Regulations as well as compliance with other applicable federal, provincial,
and territorial legislation and municipal by-laws. The issued licence dictates
activities, conditions, and restrictions for the licence holder depending on
licence permissions.
A
Dealer’s Licence could allow for the following activities:
● Procurement
of controlled substances, including by import, synthesis, propagation,
cultivation and harvesting of psychedelic mushrooms for psilocybin extraction
●
Research and manufacture of controlled
substances such as psilocybin and psilocin
●
Business to business sale of controlled
substances, including by export
● Sale of
controlled substance via pharmacies
Pure
Extracts CEO, Ben Nikolaevsky, remarked, “Having the support of one of Canada’s
premiere consulting companies with subject matter proficiency in cannabis and
other regulated consumer product industries assures that we will submit a
fully-compliant Dealers Licence application to Health Canada in the shortest
time possible. As a plant-based extractor bringing functional mushroom products
to market in Q1 2021, we are very excited to be laying the groundwork for our
move into the controlled substances world of psychedelics.”
Having
the ability to do extraction research and development into psychedelic
compounds such as psilocybin and psilocin will prepare Pure Extracts to work
with partners such as medical doctors, pharmaceutical company and pharmacies as
clinical trials lead to the legalization of psychedelics and the advancement of
micro-dosing in the near future.
Submission
of the Company’s Dealer’s Licence application is subject to compliance with
applicable securities laws, including any necessary approvals by the CSE.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Investors can trade these stocks
and other ideas on our site using our list of top stock trading
apps including Robinhood, Acorn,
Stash and others.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news,
articles, podcasts and
stock directory
Subscribe to:
Posts (Atom)
-
Investorideas.com - Cannabis Stock News: TransCanna (CSE: TCAN) Product Ranks in Leafly's Top Cannabis Strains List
-
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ...